In a news release issued on Friday, manufacturer GSK said a randomized clinical trial showed the vaccine, called Arexvy, was 82 per cent effective at preventing lower respiratory tract disease caused by RSV compared to seniors who got a placebo.
For most people, including children, RSV usually causes a mild infection that goes away within a couple of weeks, according to the Public Health Agency of Canada’s website.There is no RSV vaccine for children, but there are two kinds of antibody injections that can be given to high-risk babies to help prevent serious illness.
A new antibody drug – nirsevimab, also known by the brand name Beyfortus – was approved by Health Canada in April. Nirsevimab only requires one injection to protect babies during the RSV season. It’s not yet known how widely it will be recommended for babies in Canada this fall.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CTVNews - 🏆 1. / 99 Read more »
Source: TheHillTimes - 🏆 11. / 79 Read more »
Source: ottawasuncom - 🏆 4. / 92 Read more »
Source: ctvottawa - 🏆 29. / 67 Read more »
Source: ctvottawa - 🏆 29. / 67 Read more »